PrEP: latest news

PrEP resources

  • How to get PrEP in the UK

    NHS services in the UK cannot currently provide PrEP.But it is legal to buy PrEP drugs online and import them for your personal use.To use PrEP safely, you...

    From: Factsheets

    Information level Level 2
  • Pre-exposure prophylaxis (PrEP)

    PrEP is highly effective in preventing the sexual transmission of HIV. For PrEP to work well, it’s important to take the pills regularly.While PrEP can...

    From: Factsheets

    Information level Level 2
  • Using anti-HIV drugs to prevent HIV

    The goal of HIV treatment is an undetectable viral load. An undetectable viral load means that your blood has a level of HIV below the level which...

    From: Booklets

    Information level Level 2
  • PrEP

    This briefing paper provides an overview of pre-exposure prophylaxis (PrEP) for people planning, commissioning or providing HIV prevention activities in the UK. It does this by reviewing...

    From: HIV prevention briefing papers

  • Pre-exposure prophylaxis

    Pre-exposure prophylaxis is an experimental HIV-prevention strategy that would use antiretrovirals (ARVs) to protect HIV-negative people from HIV infection....

    From: Preventing HIV

    Information level Level 4

PrEP features

PrEP news from aidsmap

More news

PrEP news selected from other sources

  • BHIVA response to The Irish Times article 'Anti-HIV drug removes personal responsibility'

    This piece has generated a considerable amount of concern in the HIV community already as its content is completely at odds with current recommendations by the World Health Organisation and NICE which recognise that HIV pre-exposure prophylaxis (PrEP) is an important component of HIV prevention. Numerous studies have shown that PrEP is a highly clinically and cost-effective safe intervention which reduces the risk of becoming infected with HIV by around 90%.

    24 April 2017 | BHIVA
  • Anti-HIV drug removes personal responsibility

    I would argue that Pre-exposure Prophylaxis is a solution which removes personal responsibility in relation to the transmission of HIV, increases the practice of unprotected sexual behaviour and will, ultimately, be responsible for widespread liver disease among gay populations in 10-15 years from now.

    20 April 2017 | Irish Times
  • Open letter to Gilead Sciences about PrEP by EATG and the PrEP in Europe Initiative

    Please read and share this letter signed by the European AIDS Treatment Group and the PrEP in Europe Initiative (PEI), a partnership of European prevention and policy NGOs. It requests Gilead Sciences to surrender their patent of Truvada® or otherwise make it possible for Truvada or generic equivalents of it to be offered at greatly reduced prices to all European health care systems so that it can be used as HIV pre-exposure prophylaxis (PrEP).

    18 April 2017 | EATG / PrEP in Europe
  • HIV notifications down 16 per cent in Queensland compared to same period in 2016

    There have been 48 HIV notifications in Queensland until April 2, compared with 57 to the same period in 2016.

    18 April 2017 | Brisbane Times
  • Sex, drugs and activism: making HIV treatment as prevention available in the UK

    The Scottish pathway to the PrEP policy decision has been very different to that of England.

    13 April 2017 | Sociology Lens
  • PrEP marketing campaigns get homoerotic. It’s about time.

    Shirtless lucha libre Mexican wrestlers diving into bed are part of a colorful new print ad campaign promoting “health and sex” for Gilead Sciences, the pharma maker of HIV prevention drug Truvada.

    11 April 2017 | Queerty
  • Update on PrEP Impact trial in England

    The trial protocol is complete, trial participant eligibility criteria have been endorsed by experts in the field and by community representatives, and independent peer review has been conducted. The Medicines and Healthcare products Regulatory Agency (MHRA) has been consulted about trial categorisation and a relevant opinion received. Submission for ethics committee approval is imminent. Our aim is to have the trial started by the summer of 2017.

    10 April 2017 | Public Health England
  • How do you do it? Australian HIV campaign puts emphasis on a combination of ways

    Meet Tom, Dick and Harry. Sydney-based health promotion organization ACON’s current campaign singles out different men who “do it”, but who opt for different ways of protecting themselves. “We all have notions of what safe sex means, but we wanted to reflect actual behaviour among gay men and other men who have sex with men,” said ACON Chief Executive Officer Nicolas Parkhill.

    05 April 2017 | UNAIDS
  • What's Reckless About a Campaign to Prevent HIV?

    F*ck w/out Fear is the tagline of the Los Angeles LGBT Center’s new campaign to raise awareness about pre-exposure prophylaxis. We should be lauding a campaign that’s helping to boost awareness and the use of PrEP rather than taking its tagline out of context and complaining about language some find vulgar.

    03 April 2017 | The Advocate
  • Where Is PrEP? HIV Charities Warn The NHS Will Miss Its Own Deadline

    Britain's top HIV organisations have accused NHS England of dragging its feet in providing the prevention drug, despite 17 people a day contracting the virus.

    30 March 2017 | BuzzFeed
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.